Shire to file license application for Replagal
Shire has revealed that it plans to file a biologics license application for its enzyme replacement therapy for Fabry disease Replagal.
Shire, a global specialty biopharmaceutical company, announced Friday that it has officially opened a new representative office in Japan and has appointed Soh Fujiwara as Managing Director for Japanese operations.